Ozempic and Gastroparesis: What Are the Risk Factors?

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Science to Targeted Drug Safety

If you're taking Ozempic and experiencing nausea, vomiting, or abdominal pain, you may be concerned about gastroparesis—a condition where stomach emptying is delayed. Decades of pharmacovigilance and clinical research have established a framework for evaluating drug safety, and recent attention has focused on GLP-1 receptor agonists like Ozempic. This page examines the evidence on risk factors for Ozempic-associated gastroparesis, helping you understand the current medical understanding.

Understanding the Pharmacological Link Between Ozempic and Gastroparesis

Ozempic (semaglutide) is a glucagon-like peptide 1 (GLP-1) receptor agonist approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Its mechanism of action involves slowing gastric emptying, which can contribute to gastrointestinal adverse effects. Gastroparesis, a condition characterized by delayed gastric emptying without mechanical obstruction, presents with symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical diagnosis typically involves gastric emptying scintigraphy or breath tests. The link between Ozempic and gastroparesis arises from its pharmacological effect on gastric motility, which may exacerbate or unmask underlying gastroparesis in susceptible individuals. Clinical trial data from the Ozempic prescribing information show that gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo. In the pool of placebo-controlled trials, gastrointestinal adverse reactions occurred in 15.3% of placebo patients, 32.7% of those on Ozempic 0.5 mg, and 36.4% of those on Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions compared to placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently with the 2 mg dose (34.0%) versus the 1 mg dose (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate a dose-dependent increase in gastrointestinal side effects, which are consistent with the drug's effect on gastric emptying.

Clinical Evidence and Risk Considerations for Gastroparesis

Specific gastrointestinal adverse reactions reported at frequencies less than 5% include dyspepsia (placebo 1.9%, Ozempic 0.5 mg 3.5%, Ozempic 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While gastroparesis is not explicitly listed in these trial data, the symptoms overlap significantly with those of gastroparesis, and the drug's known effect on gastric motility provides a mechanistic pathway. GLP-1 receptor agonists like semaglutide delay gastric emptying by inhibiting antral contractions and stimulating pyloric tone, which can lead to prolonged gastric retention. In patients with pre-existing gastroparesis or those who develop severe gastric stasis, this effect may result in clinically significant harm. Risk considerations for affected patients include the adequacy of warnings in the prescribing information. The label does not specifically mention gastroparesis as a contraindication or warning, but it does note that Ozempic has not been studied in patients with a history of pancreatitis and recommends considering other antidiabetic therapies in such patients (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The absence of a specific gastroparesis warning may leave patients and clinicians unaware of the potential risk, particularly in those with underlying gastric motility disorders. Causation considerations require evaluating the temporal relationship between Ozempic exposure and the onset of gastroparesis symptoms. The timeline between exposure and documented harm can vary; symptoms often emerge during dose escalation, as noted in clinical trials where the majority of nausea, vomiting, and diarrhea occurred during this period (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, delayed onset is possible, and persistent symptoms after drug initiation may indicate drug-induced gastroparesis. For patients who develop gastroparesis while on Ozempic, management may involve discontinuing the drug, as gastrointestinal adverse reactions often resolve after cessation. The high discontinuation rates due to gastrointestinal effects (3.1% for 0.5 mg and 3.8% for 1 mg) suggest that these symptoms are clinically significant (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In cases where harm has occurred, affected individuals may need to consider alternative diabetes treatments that do not delay gastric emptying, such as metformin or insulin. The mechanistic pathway linking Ozempic to gastroparesis is well-supported by its pharmacology, and the clinical trial data confirm a higher incidence of gastrointestinal adverse reactions compared to placebo. However, the lack of a specific gastroparesis warning in the label may represent a gap in risk communication. Patients with a history of gastroparesis or other gastric motility disorders should be counseled about this potential risk before starting Ozempic, and clinicians should monitor for symptoms during treatment.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the connection between Ozempic and gastroparesis?

Ozempic (semaglutide) slows gastric emptying as part of its mechanism of action. This can exacerbate or unmask gastroparesis, a condition of delayed gastric emptying, in susceptible individuals. Clinical trials show higher rates of gastrointestinal adverse reactions in Ozempic users compared to placebo, with symptoms overlapping those of gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Does the Ozempic label warn about gastroparesis?

No, the prescribing information does not specifically mention gastroparesis as a contraindication or warning. However, it notes gastrointestinal adverse reactions and recommends caution in patients with a history of pancreatitis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). This gap may leave patients and clinicians unaware of the potential risk.

What should I do if I develop gastroparesis symptoms while taking Ozempic?

If you experience persistent nausea, vomiting, bloating, or abdominal pain after starting Ozempic, consult your healthcare provider. Discontinuation of the drug often leads to resolution of symptoms. Alternative diabetes treatments that do not delay gastric emptying, such as metformin or insulin, may be considered.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Ozempic Prescribing Information (DailyMed)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.